229 related articles for article (PubMed ID: 32251624)
1. Non-small-cell lung cancer brain metastases and PD-(L)1 immune checkpoint inhibitors.
Barlesi F; Tomasini P
Lancet Oncol; 2020 May; 21(5):607-608. PubMed ID: 32251624
[No Abstract] [Full Text] [Related]
2. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.
Vilariño N; Bruna J; Bosch-Barrera J; Valiente M; Nadal E
Cancer Treat Rev; 2020 Sep; 89():102067. PubMed ID: 32682248
[TBL] [Abstract][Full Text] [Related]
3. Immune Checkpoint Inhibitors in Brain Metastases: From Biology to Treatment.
Berghoff AS; Venur VA; Preusser M; Ahluwalia MS
Am Soc Clin Oncol Educ Book; 2016; 35():e116-22. PubMed ID: 27249713
[TBL] [Abstract][Full Text] [Related]
4. Anti-PD-(L)1 immunotherapy for brain metastases in non-small cell lung cancer: Mechanisms, advances, and challenges.
Zhou S; Xie J; Huang Z; Deng L; Wu L; Yu J; Meng X
Cancer Lett; 2021 Apr; 502():166-179. PubMed ID: 33450361
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of immune checkpoint blockade for brain metastases.
Harary M; Reardon DA; Iorgulescu JB
CNS Oncol; 2019 Jun; 8(2):CNS33. PubMed ID: 30854898
[No Abstract] [Full Text] [Related]
6. Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors.
Hendriks LEL; Henon C; Auclin E; Mezquita L; Ferrara R; Audigier-Valette C; Mazieres J; Lefebvre C; Rabeau A; Le Moulec S; Cousin S; Duchemann B; le Pechoux C; Botticella A; Ammari S; Gazzah A; Caramella C; Adam J; Lechapt E; Planchard D; De Ruysscher D; Dingemans AM; Besse B
J Thorac Oncol; 2019 Jul; 14(7):1244-1254. PubMed ID: 30780002
[TBL] [Abstract][Full Text] [Related]
7. Separating or combining immune checkpoint inhibitors (ICIs) and radiotherapy in the treatment of NSCLC brain metastases.
Li W; Yu H
J Cancer Res Clin Oncol; 2020 Jan; 146(1):137-152. PubMed ID: 31813004
[TBL] [Abstract][Full Text] [Related]
8. There and back again: An immunotherapy tale.
Guo Y; Krupnick AS
J Thorac Cardiovasc Surg; 2018 Apr; 155(4):1771-1774. PubMed ID: 29409610
[No Abstract] [Full Text] [Related]
9. KEYNOTE-024: Unlocking a pathway to lung cancer cure?
Rusch VW; Chaft J; Hellmann M
J Thorac Cardiovasc Surg; 2018 Apr; 155(4):1777-1780. PubMed ID: 29395215
[No Abstract] [Full Text] [Related]
10. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Herzberg B; Campo MJ; Gainor JF
Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
[TBL] [Abstract][Full Text] [Related]
11. [Progress of Immunotherapy Mechanisms and Current Evidence of PD-1/PD-L1
Checkpoint Inhibitors for Non-small Cell Lung Cancer with Brain Metastasis].
Sheng J; Yu X; Li H; Fan Y
Zhongguo Fei Ai Za Zhi; 2020 Nov; 23(11):976-982. PubMed ID: 32773010
[TBL] [Abstract][Full Text] [Related]
12. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
13. Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders.
Leonardi GC; Gainor JF; Altan M; Kravets S; Dahlberg SE; Gedmintas L; Azimi R; Rizvi H; Riess JW; Hellmann MD; Awad MM
J Clin Oncol; 2018 Jul; 36(19):1905-1912. PubMed ID: 29746230
[TBL] [Abstract][Full Text] [Related]
14. Combination Therapy of Radiotherapy and Anti-PD-1/PD-L1 Treatment in Non-Small-cell Lung Cancer: A Mini-review.
Takamori S; Toyokawa G; Takada K; Shoji F; Okamoto T; Maehara Y
Clin Lung Cancer; 2018 Jan; 19(1):12-16. PubMed ID: 28739315
[TBL] [Abstract][Full Text] [Related]
15. The forgotten role of adjuvant immune checkpoint inhibitors in preventing melanoma brain metastasis.
El Rassy E; Farhat F; Kattan J
Immunotherapy; 2018 Nov; 10(15):1289-1291. PubMed ID: 30474477
[No Abstract] [Full Text] [Related]
16. Anti PD-1 and PDL-1 Immunotherapy in the Treatment of Advanced Non- Small Cell Lung Cancer (NSCLC): A Review on Toxicity Profile and its Management.
Sgambato A; Casaluce F; Sacco PC; Palazzolo G; Maione P; Rossi A; Ciardiello F; Gridelli C
Curr Drug Saf; 2016; 11(1):62-8. PubMed ID: 26412670
[TBL] [Abstract][Full Text] [Related]
17. Clinical benefit to programmed death-1 inhibition for non-small-cell lung cancer is associated with higher blood eosinophil levels.
Sibille A; Henket M; Corhay JL; Louis R; Duysinx B
Acta Oncol; 2020 Mar; 59(3):257-259. PubMed ID: 31755328
[No Abstract] [Full Text] [Related]
18. Clinical Outcomes in Patients With Metastatic Lung Cancer Treated With PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy.
Hwang WL; Niemierko A; Hwang KL; Hubbeling H; Schapira E; Gainor JF; Keane FK
JAMA Oncol; 2018 Feb; 4(2):253-255. PubMed ID: 28973343
[TBL] [Abstract][Full Text] [Related]
19. Machine learning-based predictors for immune checkpoint inhibitor therapy of non-small-cell lung cancer.
Wiesweg M; Mairinger F; Reis H; Goetz M; Walter RFH; Hager T; Metzenmacher M; Eberhardt WEE; McCutcheon A; Köster J; Stuschke M; Aigner C; Darwiche K; Schmid KW; Rahmann S; Schuler M
Ann Oncol; 2019 Apr; 30(4):655-657. PubMed ID: 30753264
[No Abstract] [Full Text] [Related]
20. Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer.
Lim SW; Ahn MJ
Korean J Intern Med; 2019 Jan; 34(1):50-59. PubMed ID: 30612418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]